All News
Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.
Eric Dein ejdein1 ( View Tweet)
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Read ArticleMeral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Peter Nash drpnash ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
Eric Dein ejdein1 ( View Tweet)
Eric Dein ejdein1 ( View Tweet)
Dr. Rachel Tate uptoTate ( View Tweet)